Recent Updates
Recently added Catalysts

Diazepam Buccal Film

Phase 2

Epilepsy | Small molecule | Neurology |Aquestive Therapeutics, Inc.|Last Updated: May 26, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials3
Total Enrollment90

FDA Designations

No designations recorded

Clinical trial landscape

Diazepam Buccal Film · 3 trials · 1 indication

Phase 2 2Phase 1 1
NCT03222349Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With EpilepsyEpilepsy
COMPLETED24 Analytics
NCT03179891Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With EpilepsyEpilepsy
COMPLETED35 Analytics
PHASE2COMPLETED
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
EpilepsyUnlock trial analytics
PHASE2COMPLETED
Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy
EpilepsyUnlock trial analytics

Study Endpoints

Primary Endpoints

Area Under the Concentration Time Curve (AUC) 0 to 4 Hours Post-dose
Time 0 (dosing), 0.25, 0.5, 1, 1.5, 2, 4 hours post-dose

AUC calculated from time 0 (dosing) to 4 hours post-dose in both Period A (interictal administration) and Period B (ictal/peri-ictal administration)

Area Under the Concentration Time Curve (AUC) From 0 to 2 Hours Post-dose
Time 0 (dosing), 0.25, 0.5, 1, 1.5, 2 hours post-dose

AUC calculated from time 0 (dosing) to 2 hours post-dose in both Period A (interictal administration) and Period B (ictal/peri-ictal administration)Period A (interictal administration) and Period B (ictal/peri-ictal administration)

Time When Maximum Plasma Concentration Was Observed (Tmax) 0 to 2 Hours Post-dose
Time 0 (dosing), 0.25, 0.5, 1, 1.5, 2 hours post-dose

Tmax calculated from time 0 (dosing) to 2 hours post-dose in both Period A (interictal administration) and Period B (ictal/peri-ictal administration)

Time When Maximum Plasma Concentration Was Observed (Tmax) 0-4 Hours Post-Dose
Time 0 (dosing), 0.25, 0.5, 1, 1.5, 2, 4 hours post-dose

Tmax calculated from dosing (Time 0) to 4 hours post-dose in both Period A (interictal administration) and Period B (ictal/peri-ictal administration)

Observed Maximum Plasma Concentration (Cmax) 0-2 Hours
Time 0 (dosing), 0.25, 0.5, 1, 1.5, 2 hours post-dose

Maximum observed plasma concentration measured from Time 0 to 2 hours post-dose in Period A (interictal administration) and Period B (ictal/peri-ictal administration)

Observed Maximum Plasma Concentration (Cmax) From Time 0 (Dosing) to 4 Hours Post-dose
Time 0 (dosing), 0.25, 0.5, 1, 1.5, 2, 4 hours post-dose

Maximum observed plasma concentration from Time 0 to 4 hours post-dose in Period A (interictal administration) and Period B (ictal/peri-ictal administration)

Tmax Pharmacokinetic EndPoints
-2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours

Observed time to reach maximum drug concentration (Tmax)

Cmax Pharmacokinetic EndPoints
-2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours

Observed Peak Drug Concentration (Cmax)

Area Under the Plasma Concentration Curve Pharmacokinetic EndPoints
-2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours

Area under the Plasma Concentration -time curve from time zero until the last measured time (AUC0-t)

AUC 0-t
0.5, 0.75, 1, 105, 2, 3, 4, 6, 9, 12, 24, 48, 72, 96, 120, 144, 192, and 240 hours post-dose

Area Under Plasma Concentration-Time Curve From Time Zero to the last non-zero concentration

AUC 0-inf
0.5, 0.75, 1, 105, 2, 3, 4, 6, 9, 12, 24, 48, 72, 96, 120, 144, 192, and 240 hours post-dose

Area under concentration time curve, from time 0 extrapolated to infinity

Cmax
0.5, 0.75, 1, 105, 2, 3, 4, 6, 9, 12, 24, 48, 72, 96, 120, 144, 192, and 240 hours post-dose

Maximum observed plasma concentration

Secondary Endpoints

Usability of Diazepam Buccal Film: Number of Subjects Who Spit Out/Moved/Chewed the Film After it Adhered (Stuck) to Buccal Mucosa During Period A and Period B.
Period A and Period B from the time of first attempt at DBF insertion to 15 minutes after insertion.
Usability of Diazepam Buccal Film: Unsuccessful Attempts
Period A and Period B from the time of first attempt at DBF insertion to 15 minutes after insertion.
Usability Endpoint : Amount of Saliva That Exited the Mouth After DBF Dosing
Period A and Period B from the time of first attempt at DBF insertion to 15 minutes after insertion.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Interictal PeriodEXPERIMENTALEach subject received a single dose of DBF based on the subject's age and weight.
Ictal/Peri-ictal PeriodEXPERIMENTALEach subject received a single dose of DBF based on the subject's age and weight.
Diazepam Buccal Film, Then Diastat Rectal GelEXPERIMENTALParticipants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
Diastat Rectal Gel, Then Diazepam Buccal FilmEXPERIMENTALParticipants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
Diazepam Buccal Film following a High-Fat MealEXPERIMENTALParticipants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.

Interventions

NameTypeDescription
Diazepam Buccal FilmDRUGSubjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
Diazepam Buccal Film 12.5 mgDRUGAll subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
Diastat® Rectal Gel (Valeant Pharmaceuticals USA)DRUGDiastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
Unlock Study Design Details

Eligibility Criteria

Age Range2 Years to 16 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: Potential subjects meeting all of the following criteria may be included in the study: 1. Subjects have a clinical diagnosis of epilepsy (GTC seizures or focal seizures with impaired awareness) and were scheduled for admission to an Epilepsy Monitoring Unit (EMU), General Clini...

Countries:United States
Unlock Eligibility Criteria